[1] 刘明波, 王增武, 樊静, 等. 《中国心血管健康与疾病报告2023》要点解读[J]. 中国心血管病研究,2024,22(7):577-593.
[2] TABARES-GUEVARA JH, VILLA-PULGARIN JA, HERNANDEZ JC. Atherosclerosis: immunopathogenesis and strategies for immunotherapy. Immunotherapy. 2021;13(14): 1231-1244.
[3] 卜军, 陈章炜, 崔晓通, 等. 中国成人代谢异常与心血管疾病防治[J]. 上海医学,2020, 43(3):129-164.
[4] MAKI KC, KIRKPATRICK CF, CHEELEY MK, et al. Statin-Associated Muscle Symptoms: Identification and Recommendations for Management. Curr Atheroscler Rep. 2024; 27(1):5.
[5] RASTEGAR TF, KHAN IA, CHRISTOPHER-STINE L. Decoding the Intricacies of Statin-Associated Muscle Symptoms. Curr Rheumatol Rep. 2024; 26(7):260-268.
[6] HLATKY MA, GONZALEZ PE, MANSON JE, et al. Statin-Associated Muscle Symptoms Among New Statin Users Randomly Assigned to Vitamin D or Placebo. JAMA Cardiol. 2023; 8(1):74-80.
[7] HONG D, LEE J, LEE H, et al. Cost-Effectiveness of Intravascular Imaging-Guided Complex PCI: Prespecified Analysis of RENOVATE-COMPLEX-PCI Trial. Circ Cardiovasc Qual Outcomes. 2024;17(3):e010230.
[8] MEHAFFEY J H, HAYANGA J, KAWSARA M, et al. Contemporary Coronary Artery Bypass Grafting vs Multivessel Percutaneous Coronary Intervention. Ann Thorac Surg. 2023;116(6):1213-1220.
[9] 袁一顺, 刘中勇. 基于“脾气散精”理论探讨内质网应激与动脉粥样硬化的相关性及中医药干预策略[J]. 中国老年学杂志, 2025,45(9):2285-2290.
[10] 栾玉洁, 袁晨露, 陈子真, 等. 基于积证理论运用攻、消、补、散法分期干预动脉粥样硬化的思路[J]. 中医杂志,2025,66(7): 685-689.
[11] 张静怡, 陈纪烨, 于宗良, 等. 瘀毒脉积与泛血管疾病诊疗思路探析[J].中国中西医结合杂志,2025,45(2):235-240.
[12] 王阶, 李军, 董艳, 等. 泛血管疾病的中医内涵及防治策略[J]. 中国实验方剂学杂志, 2025,31(7):1-14.
[13] 动脉粥样硬化中西医防治专家共识(2021年)[J]. 中国中西医结合杂志,2022,42(3): 287-293.
[14] 曹盼夏, 彭紫凝, 刘珊珊, 等. 腺苷酸活化蛋白激酶介导巨噬细胞脂肪酸氧化:中药防治动脉粥样硬化的途径[J]. 中国组织工程研究,2025,29(18):3906-3914.
[15] 马奕敏, 苏和, 郑晨宏. 中医药及相关疗法干预动脉粥样硬化炎性因子TNF-α、IL-6的研究进展[J]. 辽宁中医杂志,2024, 51(11):217-220.
[16] 梁清芝, 陈正涛, 周若然, 等. 内质网应激在动脉粥样硬化中的作用及中医药调控研究进展[J]. 中国实验方剂学杂志,2024, 30(5):226-235.
[17] 张艺嘉, 樊珂, 崔小数, 等. 崔应珉辨治动脉粥样硬化经验[J]. 中医学报,2020,35(11): 2376-2379.
[18] 曹珊, 张艺嘉, 白杨, 等. 基于消斑通脉方抗动脉粥样硬化作用机制的网络药理学分析和体外实验验证[J]. 吉林大学学报(医学版), 2024,50(4):925-938.
[19] CAO Y, JING P, YU L, et al. miR-214-5p/C1QTNF1 axis enhances PCV2 replication through promoting autophagy by targeting AKT/mTOR signaling pathway. Virus Res. 2023;323:198990.
[20] 李帅帅, 于红红, 田维毅. 中医药通过调节microRNAs干预动脉粥样硬化研究进展[J]. 时珍国医国药,2021,32(8):1968-1971.
[21] JAKUBOWSKI H, WITUCKI L. Homocysteine Metabolites, Endothelial Dysfunction, and Cardiovascular Disease. Int J Mol Sci. 2025; 26(2):746.
[22] ZHU K, LIU C, GUO X, et al. Exosomal miR-126-3p: Potential protection against vascular damage by regulating the SLC7A5/mTOR Signalling pathway in human umbilical vein endothelial cells. Scand J Immunol. 2024;99(4): e13354.
[23] CHEN W, CUI F, FAN J, et al. The Diagnostic and Prognostic Value of Circulating miR-126-3p and miR-145-5p in Coronary Artery Calcification Lesions. Catheter Cardiovasc Interv. 2025;106(2):780-791.
[24] LEISTNER DM, BOECKEL JN, REIS SM, et al.Transcoronary gradients of vascular miRNAs and coronary atherosclerotic plaque characteristics. Eur Heart J. 2016;37(22): 1738-1749.
[25] PANGHALIA A, SINGH V. Machine learning approaches for predicting the small molecule-miRNA associations: a comprehensive review. Mol Divers. 2025;29(4):3825-3856.
[26] HAN GS, GAO Q, PENG LZ, et al. Hessian Regularized L2,1-Nonnegative Matrix Factorization and Deep Learning for miRNA-Disease Associations Prediction. Interdiscip Sci. 2024;16(1):176-191.
[27] MONACO C, MCNAMARA CA, SLUTTER B, et al.Immunotherapy for atherosclerosis.Physiol Rev. 2025;105(4):2141-2230.
[28] WANG H, TIAN Q, ZHANG R, et al. Nobiletin alleviates atherosclerosis by inhibiting lipid uptake via the PPARG/CD36 pathway. Lipids Health Dis. 2024;23(1):76.
[29] 张青, 杜高辉, 魏宇淼.支架内新生动脉粥样硬化的研究进展[J]. 华中科技大学学报(医学版),2024,53(4):545-551.
[30] CAO H, JIA Q, YAN L, et al. Quercetin Suppresses the Progression of Atherosclerosis by Regulating MST1-Mediated Autophagy in ox-LDL-Induced RAW264.7 Macrophage Foam Cells. Int J Mol Sci. 2019;20(23):6093.
[31] 刘芳. 基于TLR4/MyD88/NF-κB通路的炎症调控作用探讨益气养阴活血化痰方抗动脉粥样硬化的效应机制研究[D]. 南京:南京中医药大学,2022.
[32] ZHAO D, LIU J, WANG M, et al. Epidemiology of cardiovascular disease in China: current features and implications. Nat Rev Cardiol. 2019;16(4):203-212.
[33] KARERE GM, GLENN JP, LI G, et al. Potential miRNA biomarkers and therapeutic targets for early atherosclerotic lesions. Sci Rep. 2023; 13(1):3467.
[34] ZAPATA-MARTINEZ L, AGUILA S, DE LOS RA, et al. Inflammatory microRNAs in cardiovascular pathology: another brick in the wall. Front Immunol. 2023;14:1196104.
[35] CHEN X, CAO Y, GUO Y, et al. microRNA-125b-1-3p mediates autophagy via the RRAGD/mTOR/ULK1 signaling pathway and mitigates atherosclerosis progression. Cell Signal. 2024; 118:111136.
[36] WANG C, LIU C, SHI J, et al.Nicotine exacerbates endothelial dysfunction and drives atherosclerosis via extracellular vesicle-miRNA. Cardiovasc Res. 2023;119(3):729-742.
[37] HUANG P, HE XY, XU M. The Role of miRNA-146a and Proinflammatory Cytokines in Carotid Atherosclerosis. Biomed Res Int. 2020; 2020:6657734.
[38] ZENG P, YANG J, LIU L, et al.ERK1/2 inhibition reduces vascular calcification by activating miR-126-3p-DKK1/LRP6 pathway. Theranostics. 2021;11(3):1129-1146.
[39] WASSAIFI S, KAEFFER B, ZARROUK S. Cellular Phenotypic Transformation During Atherosclerosis: The Potential Role of miRNAs as Biomarkers. Int J Mol Sci. 2025; 26(5):2083.
[40] MARTINEZ-ARROYO O, ORTEGA A, FLORES-CHOVA A, et al. High miR-126-3p levels associated with cardiovascular events in a general population. Eur J Intern Med. 2023; 113:49-56.
[41] LIN X, OUYANG S, ZHI C, et al. Focus on ferroptosis, pyroptosis, apoptosis and autophagy of vascular endothelial cells to the strategic targets for the treatment of atherosclerosis. Arch Biochem Biophys. 2022;715:109098.
[42] GROS F, MULLER S. The role of lysosomes in metabolic and autoimmune diseases. Nat Rev Nephrol. 2023;19(6):366-383.
[43] MARTINET W, DE MEYER GR. Autophagy in atherosclerosis: a cell survival and death phenomenon with therapeutic potential. Circ Res. 2009;104(3):304-317.
[44] MIAO J, ZANG X, CUI X, et al. Autophagy, Hyperlipidemia, and Atherosclerosis. Adv Exp Med Biol. 2020;1207:237-264.
[45] ZHANG Y, WENG J, HUAN L, et al. Mitophagy in atherosclerosis: from mechanism to therapy. Front Immunol. 2023;14:1165507.
[46] HU G, YUAN Z, WANG J. Autophagy inhibition and ferroptosis activation during atherosclerosis: Hypoxia-inducible factor 1alpha inhibitor PX-478 alleviates atherosclerosis by inducing autophagy and suppressing ferroptosis in macrophages. Biomed Pharmacother. 2023;161:114333.
[47] LEE JS, KIM YH, JHUN J, et al. Oxidized LDL Accelerates Cartilage Destruction and Inflammatory Chondrocyte Death in Osteoarthritis by Disrupting the TFEB-Regulated Autophagy-Lysosome Pathway. Immune Netw. 2024;24(3):e15.
[48] 粟裕冬, 张敬, 李慧歆, 等. 中医药调控MAPK通路防治疾病的研究进展[J].中国处方药, 2023,21(10):182-188.
[49] YAN Y, DAI T, GUO M, et al. A review of non-classical MAPK family member, MAPK4: A pivotal player in cancer development and therapeutic intervention. Int J Biol Macromol. 2024;271(Pt 2):132686.
[50] QI XM, CHEN G. p38gamma MAPK Inflammatory and Metabolic Signaling in Physiology and Disease. Cells. 2023;12(13): 1674.
[51] WANG X, LIU R, LIU D. The Role of the MAPK Signaling Pathway in Cardiovascular Disease: Pathophysiological Mechanisms and Clinical Therapy.Int J Mol Sci. 2025;26(6):2667.
[52] 霍宏磊, 曹灿, 刘笑迎, 等. MAPK信号通路在动脉粥样硬化中的作用及中药干预研究进展[J]. 现代中西医结合杂志,2024, 33(24):3499-3504.
[53] LUO G, XIANG L, XIAO L. Quercetin alleviates atherosclerosis by suppressing oxidized LDL-induced senescence in plaque macrophage via inhibiting the p38MAPK/p16 pathway. J Nutr Biochem. 2023;116:109314.
[54] CHU T, WANG Y, WANG S, et al. Kaempferol regulating macrophage foaming and atherosclerosis through Piezo1-mediated MAPK/NF-kappaB and Nrf2/HO-1 signaling pathway. J Adv Res. 2024;17:S2090-1232(24) 00535-6.
[55] HUANG R, SUN Y, LIU R, et al. ZeXieYin formula alleviates atherosclerosis by inhibiting the MAPK/NF-kappa B signaling pathway in APOE-/- mice to attenuate vascular inflammation and increase plaque stability. J Ethnopharmacol.2024;327:117969.
[56] 刘继东, 樊程程, 王天朗, 等. 化瘀祛痰方调控MAPK通路对AS小鼠主动脉巨噬细胞的影响及机制研究[J]. 时珍国医国药, 2024,35(6):1357-1360.
[57] CAPETINI VC, QUINTANILHA BJ, DE OLIVEIRA DC, et al. Blood orange juice intake modulates plasma and PBMC microRNA expression in overweight and insulin-resistant women: impact on MAPK and NFkappaB signaling pathways. J Nutr Biochem. 2023;112:109240.
[58] ZHAO C, SUN G, LI Y, et al. Forkhead box O3 attenuates osteoarthritis by suppressing ferroptosis through inactivation of NF-kappaB/MAPK signaling. J Orthop Translat. 2023;39:147-162.
[59] ZHOU Y, MING J, LI Y, et al. Exosomes derived from miR-126-3p-overexpressing synovial fibroblasts suppress chondrocyte inflammation and cartilage degradation in a rat model of osteoarthritis. Cell Death Discov. 2021;7(1):37.
[60] LEE S, LEE D H, LEE JP, et al. Rosuvastatin activates autophagy via inhibition of the Akt/mTOR axis in vascular smooth muscle cells. Korean J Physiol Pharmacol. 2025;29(1):117-126.
[61] ZHANG X, QIN Y, WAN X, et al. Rosuvastatin exerts anti-atherosclerotic effects by improving macrophage-related foam cell formation and polarization conversion via mediating autophagic activities. J Transl Med. 2021;19(1):62.
|